1Equal contribution.
1468-3083/asset/JDV_left.gif?v=1&s=1f5077e9ad670d0243350067014f92a67f0587c2)
ORIGINAL ARTICLE
You have free access to this content
Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort
Article first published online: 7 DEC 2011
DOI: 10.1111/j.1468-3083.2011.04364.x
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology
Issue
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 1, pages 92–96, January 2013
Additional Information
How to Cite
Maire, C., Vercambre-Darras, S., Devos, P., D’Herbomez, M., Dubucquoi, S. and Mortier, L. (2013), Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort. Journal of the European Academy of Dermatology and Venereology, 27: 92–96. doi: 10.1111/j.1468-3083.2011.04364.x
Funding sources There are no financial disclosures from any authors.
Conflict of interest None declared.
- †
1Equal contribution.
Publication History
- Issue published online: 18 DEC 2012
- Article first published online: 7 DEC 2011
- Received: 26 May 2011; Accepted: 8 November 2011
- Abstract
- Article
- References
- Cited By
Abstract
Background Melanoma is an immunogenic tumour type frequently associated with spontaneous auto-immune manifestations such as spontaneous regression, vitiligo-like reactions or auto-immune retinopathy, which seem to be associated with better prognosis.
Objectives The aim of this prospective study was to evaluate the correlation between spontaneous autoimmunity and survival in patients with stage IV melanoma.
Methods From 2007 to 2008, 103 patients were studied with antithyroid and antinuclear auto antibody assays performed every 6 months. Any detectable occurrence of a spontaneous self antibody (SpSA) at the upper detection limit, at least for one assay, was considered to be a biological marker of autoimmunity.
Results Univariate and multivariate analyses confirmed significantly longer survival in the absence of known primary melanoma (P = 0.044) and in the presence of marker of biologic autoimmunity, independently of previous immunotherapy (P = 0.045).
Conclusions This prospective and comparative study is, to our knowledge, the first to report the frequency of SpSA in stage IV melanoma. Our results suggest that spontaneous autoimmunity, through a rupture of self-tolerance, is a good prognostic factor in a subgroup of patients with stage IV melanoma.